Navigation Links
Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology

Protocol for New Aggrastat Study in American Heart Journal


WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused, biopharmaceutical company, today announced that the two-year, follow-up results from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare Metal Stent In Acute Myocardial Infarction) study were published in the July edition of the Journal of the American College of Cardiology (JACC).


The article, titled, "Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction", outlines the potential benefit of AGGRASTATR (tirofiban hydrochloride) plus sirolimus-eluting stent (SES) versus ReoproR (abciximab) plus bare-metal stent (BMS) in the prevention of the cumulative incidence of death, myocardial infarction (MI), or target vessel revascularization (TVR) in acute myocardial infarction patients after two years.


At two years, the cumulative incidence of death, MI, or TVR was lower in the AGGRASTATR-SES group compared with the ReoproR-BMS group (24.2% vs. 38.6%, p@038). This statistically significant outcome at two years is similar to the previously reported eight month results that were published in The Journal of the American Medical Association (May 2005).


The positive results from STRATEGY were the impetus for an ongoing larger factorial design study titled MULTI-STRATEGY (Multicentre Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab and Sirolimus-Eluting Stent Versus Base Metal Stent in Acute Myocardial Infarction). The MULTI-STRATEGY protocol was published in the July edition of the American Heart Journal.


This 600-patient study will further assess AGGRASTATR-S
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Protox Announces Positive Clinical Data from Prostate Cancer Study
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... you may want to get screened and treated for ... According to a first-of-its-kind study in the October ... of the American Society of Anesthesiologists (ASA), patients with ... prior to surgery are less likely to develop serious ... "OSA is a common disorder that affects millions and ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry ... He is a 13-year veteran in the school, commercial and ... A-Z Bus Sales of Colton, California. While with A-Z Mr. ... top line revenues, profit and market penetration by double digits. ... to all-electric or plug-in hybrid vehicle conversions. They have ...
(Date:9/23/2014)... Carbon nanotubes serve as bridges that allow electrical ... patches invented at Rice University and Texas Children,s ... Jacot and chemical engineer and chemist Matteo Pasquali ... nanotubes. The patches are made of a sponge-like ... body,s extracellular matrix. , The nanotubes overcome a ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
Breaking Medicine News(10 mins):Health News:New research suggests sleep apnea screening before surgery 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2
... 2010 -- The American College of Cardiology and ... Interventions has been accepted for coverage by Thomson ... the Journal Citation Reports. The Journal will receive ... "The Editorial Board and the American College of Cardiology ...
... According to a ... programs, such as Medicare and Medicaid, have prompted hospitals to shift costs to automobile insurance ... hospital bills prior to payment. , ... Malvern, PA (Vocus) April 23, 2010 -- According to a new study from ...
... ... lipoplasty will be discussed by leading experts at the Annual Meeting of the American ... Convention Center April 23-27, 2010. “Point/Counterpoint – Laser Lipoplasty – Hype or Useful ... and Jeffrey M. Kenkel, MD. , ...
... at risk for facial deformities, poor grades, dentists say ... the mouth instead of the nose can lead to ... mouth breathers, most often children with allergies, have problems ... size, weight, sleep and even school performance, a recent ...
... INDIANAPOLIS Structural and functional congenital cardiovascular abnormalities present ... defects encountered in live births. Nearly half a million ... ranging in severity from relatively simple issues, such as ... severe malformations, including complete absence of one or more ...
... ... will be pleased with the final result, there is a small chance ... The realities of revision in rhinoplasty will be discussed by leading experts ... Aesthetic Plastic Surgery (ASAPS), being held at the Gaylord National Hotel and ...
Cached Medicine News:Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 2Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 4Health News:Laser Lipoplasty: Cutting Through the Hype 2Health News:Laser Lipoplasty: Cutting Through the Hype 3Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 2Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 3Health News:New strategies to improve treatment and avert heart failure in children 2Health News:New strategies to improve treatment and avert heart failure in children 3Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 2Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: